2. Inhibitory Antibodies
  3. Acapatamab

Acapatamab  (Synonyms: AMG-160)

Cat. No.: HY-P99418

Molarity Calculator

Acapatamab (AMG-160) is an anti-CD3E/FOLH1 monoclonal antibody.

For research use only. We do not sell to patients.

CAS No. : 2314491-93-3

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Acapatamab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Acapatamab (AMG-160) is an anti-CD3E/FOLH1 monoclonal antibody[1].

IC50 & Target

CD3E/FOLH1
In Vitro

Acapatamab (AMG-160; 0-10000 pM; 48 h) induces T-cell activation and increases in CD25, CD69, 4-1BB, and PD-1 expression on T cells[1].
Acapatamab (0-10000 pM; 48 h; T-cell) induces dose-dependent secretion of cytokines, including IL2, IL4, IL6, IL10, IFNγ, and TNFα[1].
Acapatamab (0-10000 pM; 48 h) induces potent lysis of prostate-specific membrane antigen (PSMA)-positive prostate cancer cell lines in cocultures with PBMC, with EC50 values of 6-42 pM[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Acapatamab Related Antibodies
In Vivo

Acapatamab (0.02-2 mg/kg; i.v.; days 16, 23, and 31) has antitumor activity and inhibits tumor growth in NOD/SCID mice with 22Rv-1 CRPC xenografts[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NOD/SCID mice with 22Rv-1 CRPC xenografts[1]
Dosage: 0.02, 0.2, and 2 mg/kg
Administration: Intravenous injection (days 16, 23, and 31)
Result: Had antitumor activity against established CRPC tumors.
CAS No.
SMILES

[Acapatamab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • (scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Acapatamab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Acapatamab2314491-93-3AMG-160AMG160AMG 160Othershalf-lifecancerT-cellcytokinesprostate-specific membrane antigenInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Acapatamab
Cat. No.:
HY-P99418
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.